Urinary tract infection (UTI) is complicated if the UTI is associated
with factors that increases colonization and decreases therapy
efficacy. Factors may include one or all of the following: Structural or
functional abnormalities of the genitourinary tract; presence of an
underlying disease that interferes with host defense mechanisms or the
patient being immunocompromised; and being infected by a multi-drug
Principles of therapy includes effective antimicrobial antimicrobial therapy, optimal management of the underlying
abnormalities or other diseases & adequate life-supporting measures.
The aminoglycoside plazomicin has demonstrated noninferiority to meropenem, a broad-spectrum carbapenem antibiotic, for treating complicated urinary tract infection (UTI) and acute pyelonephritis, with the former yielding greater microbiologic eradication as reflected by lower incidences of recurrence and relapse, according to data from the phase III EPIC* trial.
Despite a potentially lower risk of treatment failure, prescribing ciprofloxacin or cefalexin for elderly adults presenting with a urinary tract infection (UTI) at a primary care facility may not reduce their risk of sepsis-related hospitalizations, a recent study from the UK showed.
Cefiderocol demonstrated noninferiority to imipenem-cilastatin in patients with complicated urinary tract infections (UTIs) and multidrug-resistant Gram-negative infections, according to results of a phase II trial.
Targeted antibiotic prophylaxis – after a rectal swab to identify specific intestinal flora – does not appear to significantly impact the risk of urinary sepsis following a transrectal ultrasound (TRUS)-guided prostate biopsy, according to a recent study.
Meropenem-vaborbactam may be effective in improving signs and symptoms and eradicating causative pathogens in patients with complicated urinary tract infections (UTIs), the phase III TANGO I* trial showed.
A trial vaccine for the prevention of COVID-19 is underway with the first US participants being dosed in the Phase 1/2 clinical trial. Known as the BNT162 vaccine programme, the trials are a collaboration between Pfizer Inc. and BioNTech SE, and is part of a global development programme with Germany and the US taking the lead in having the first cohorts to be vaccinated. Germany started the study 1 week earlier.
Rinsing with mouthwash that contains povidone-iodine (PI) or cetylpyridinium chloride (CPC) helps reduce SARS-CoV-2 levels in the saliva of COVID-19 patients, with the effect persisting for up to 6 hours, as shown in a study from Singapore.